Brown-Elliott Barbara A, Bush Georgie, Hughes M Dolores, Rodriguez Eliana, Weikel Chase A, Min Sharon B, Wallace Richard J
The University of Texas Health Science Center at Tyler, Mycobacteria/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
Department of Infectious Diseases, GSK, Collegeville, Pennsylvania, USA.
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0168423. doi: 10.1128/aac.01684-23. Epub 2024 Apr 24.
Novel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being complex (0.25-8 µg/mL), complex (1-2 µg/mL), (0.25-8 µg/mL), and (4-16 µg/mL). Testing greater numbers of some species is suggested to better understand gepotidacin activity against NTM.
需要新型抗菌药物来治疗日益增多的非结核分枝杆菌（NTM）感染。使用标准肉汤微量稀释法，对68株NTM分离株进行了针对吉泊替尼的测试，吉泊替尼是一种新型的、同类首创的口服三氮杂萘类细菌拓扑异构酶抑制剂。最低 MIC 值（0.25至>64µg/mL）各不相同，鸟型胞内分枝杆菌复合群（Mycobacterium avium complex）为0.25 - 8µg/mL，脓肿分枝杆菌复合群（Mycobacterium abscessus complex）为1 - 2µg/mL，堪萨斯分枝杆菌（Mycobacterium kansasii）为0.25 - 8µg/mL，龟分枝杆菌（Mycobacterium chelonae）为4 - 16µg/mL。建议测试更多数量的某些菌种，以更好地了解吉泊替尼对NTM的活性。
